Tutorials › Pharmacometrics › Multiple-Dose Pharmacokinetics and Accumulation
Pharmacokinetics · PK/PD Foundations

Multiple-Dose Pharmacokinetics and Accumulation

Learn how repeated dosing changes drug concentrations over time, why accumulation occurs, how peak and trough concentrations behave, and how dosing interval and elimination half-life determine steady-state exposure.

Intermediate PK Fundamentals Multiple Dosing Clinical Pharmacology
01 · The big picture

1. What Is Multiple-Dose Pharmacokinetics?

Multiple-dose pharmacokinetics describes what happens when the same drug is administered repeatedly rather than as a single dose.

With repeated dosing, drug from a new dose is added to drug that remains from previous doses. If elimination is not complete before the next dose, concentrations can progressively increase until the system reaches a repeating pattern known as steady state.

steady-state pattern Dose 1 Dose 2 Dose 3 Repeated doses C

Repeated dosing produces overlapping concentration-time profiles. Under linear first-order conditions, the concentrations approach a stable repeating pattern as steady state is reached.

Core idea: accumulation occurs because some drug from earlier doses remains in the body when subsequent doses are administered. The amount of accumulation depends primarily on the relationship between the dosing interval and the drug's elimination rate.
02 · Superposition

2. The Key Principle: Superposition

For a linear pharmacokinetic system, the concentration produced by multiple doses can be understood as the sum of the concentration contributions from individual doses.

Suppose a single dose produces a concentration-time function \(C_1(t)\). If the same dose is given every \(\tau\) hours, then the concentration after repeated dosing is the sum of appropriately shifted single-dose profiles:

\[ C_{\text{multiple}}(t) = C_1(t)+C_1(t-\tau)+C_1(t-2\tau)+\cdots \]

This is the principle of superposition. It is one of the most useful ways to understand multiple-dose pharmacokinetics because it turns a repeated-dose problem into a series of single-dose problems.

When does this work? Superposition requires the relevant PK processes to behave approximately linearly over the dose range being considered. Nonlinear absorption, metabolism, elimination, or distribution can invalidate simple superposition.
03 · Accumulation

3. Why Does Drug Accumulate?

Consider a drug with a half-life of 8 hours that is administered every 8 hours. At the time of the second dose, the first dose has not disappeared. Approximately 50% of the first dose's contribution remains under a simple first-order model.

The second dose therefore adds drug to drug that is already present. The same process continues with later doses.

Accumulation does not mean that drug concentrations increase forever. Under linear PK and a constant dosing regimen, the amount remaining from previous doses approaches a limiting value. Eventually, each dose adds approximately the same amount of drug that is eliminated between doses.

ConceptWhat happens
First doseConcentration reflects the new dose with little or no residual drug.
Early repeated dosesNew drug is added while residual drug from earlier doses remains.
Later dosesThe concentration excursions become progressively more similar.
Steady stateThe concentration pattern repeats from one dosing interval to the next.

The degree of accumulation is therefore closely related to the fraction of drug that remains from one dosing interval to the next.

04 · Steady state

4. What Is Steady State?

Steady state is reached when, under a constant dosing regimen, the concentration-time profile repeats from one dosing interval to the next.

For intermittent dosing, steady state does not necessarily mean that concentration is constant. Instead, concentration can continue to rise and fall during each interval while the overall pattern remains stable.

Cmax,ss Cmin,ss One dosing interval, τ C

At steady state, concentrations fluctuate between reproducible peak and trough values. The pattern repeats even though concentration is not constant throughout the interval.

Important distinction: “steady state” does not mean “no fluctuation.” For intermittent dosing, it means that the fluctuation pattern has stabilized.
05 · Accumulation ratio

5. The Accumulation Ratio

For repeated dosing of a drug with first-order elimination, the accumulation ratio can be expressed as:

\[ R_{\text{acc}} = \frac{1}{1-e^{-k\tau}} \]

where:

  • \(k\) is the elimination rate constant.
  • \(\tau\) is the dosing interval.

Because:

\[ k=\frac{\ln(2)}{t_{1/2}}, \]

the accumulation ratio can also be written as:

\[ R_{\text{acc}} = \frac{1}{1-2^{-\tau/t_{1/2}}}. \]

This equation captures a central principle of multiple-dose PK: shorter dosing intervals relative to the half-life produce greater accumulation.

Dosing interval relative to half-lifeInterpretation
\(\tau \gg t_{1/2}\)Most drug is eliminated between doses; accumulation is relatively small.
\(\tau \approx t_{1/2}\)A substantial fraction remains at the next dose; accumulation is appreciable.
\(\tau < t_{1/2}\)Much of the previous dose remains; accumulation is greater.
06 · Peak and trough

6. Peak and Trough Concentrations

For intermittent dosing, two clinically important concentrations are the peak and trough.

  • Peak concentration: the concentration near the high point of the dosing interval.
  • Trough concentration: the concentration immediately before the next dose.

For an IV bolus regimen in a one-compartment model with first-order elimination, the steady-state peak concentration immediately after a dose is:

\[ C_{\max,ss} = \frac{D}{V} \frac{1}{1-e^{-k\tau}} \]

The corresponding steady-state trough immediately before the next dose is:

\[ C_{\min,ss} = C_{\max,ss}e^{-k\tau}. \]

These equations show how the same dose can produce very different peak and trough behavior depending on the dosing interval and elimination rate.

Clinical interpretation: changing the dose changes the magnitude of the concentration excursion, while changing the dosing interval changes how much drug remains before the next dose and therefore affects both accumulation and fluctuation.
07 · Dose and interval

7. Dose and Dosing Interval Work Together

A multiple-dose regimen is defined not just by the dose but by how often the dose is administered.

ChangeTypical PK consequence under linear conditions
Increase dose, same intervalHigher concentrations and greater exposure per interval.
Decrease dose, same intervalLower concentrations and lower exposure per interval.
Shorten interval, same doseMore frequent dosing and generally greater accumulation.
Lengthen interval, same doseMore time for elimination and generally less accumulation.
Increase dose while proportionally increasing intervalAverage exposure may remain similar under linear PK, but peak-trough fluctuation changes.

This is why dose selection and interval selection should be considered together. Two regimens can produce similar average exposure while producing substantially different peak and trough concentrations.

08 · Average exposure

8. Average Steady-State Concentration

For a linear system at steady state, the average concentration over a dosing interval is related to the dosing rate and clearance.

For an IV intermittent dosing regimen:

\[ C_{\text{avg},ss} = \frac{D}{CL\tau}. \]

For an extravascular regimen with bioavailability \(F\):

\[ C_{\text{avg},ss} = \frac{FD}{CL\tau}. \]

This relationship is important because it separates average exposure from within-interval fluctuation.

Key distinction: clearance and the dosing rate determine average steady-state concentration under linear PK, while the relationship between dosing interval and half-life strongly influences the size of peak-to-trough fluctuations.
09 · Time to steady state

9. How Long Does It Take to Reach Steady State?

For a drug with first-order elimination, the approach to steady state is governed by the elimination half-life.

The same approximate rule used for elimination also applies to accumulation:

Elapsed timeApproximate fraction of steady state reached
1 half-life50%
2 half-lives75%
3 half-lives87.5%
4 half-lives93.75%
5 half-lives96.875%

Thus, approximately 4–5 half-lives are commonly required to get close to steady state in a simple first-order system.

Importantly, changing the dose does not fundamentally change the time required to approach steady state when the PK is linear. The time scale is determined primarily by the elimination half-life.

10 · Loading dose

10. Why Might a Loading Dose Be Used?

If a drug requires several half-lives to approach steady state, waiting for natural accumulation may delay achievement of the desired concentration.

A loading dose can be used to place an appropriate amount of drug in the body more rapidly, followed by maintenance dosing to replace drug that is eliminated.

A simplified IV loading-dose relationship is:

\[ D_{\text{loading}} = C_{\text{target}}V \]

For an extravascular route with bioavailability \(F\):

\[ D_{\text{loading}} = \frac{C_{\text{target}}V}{F}. \]

These are simplified relationships. In real dosing decisions, the relevant target concentration, distribution volume, bioavailability, route, therapeutic window, and patient-specific factors all matter.

Conceptual distinction: a loading dose is primarily about reaching a desired concentration sooner; the maintenance regimen is primarily about replacing the amount of drug eliminated over time.
11 · Maintenance dosing

11. Maintenance Dose and Elimination

Under linear conditions, the maintenance dosing rate needed to maintain a target average concentration is related to clearance:

\[ \text{Maintenance dosing rate} = C_{\text{target}}CL. \]

For intermittent dosing:

\[ D_{\text{maintenance}} = \frac{C_{\text{target}}CL\tau}{F}. \]

This equation emphasizes an important principle: maintenance dosing is closely linked to clearance.

If clearance increases while the dose and interval remain unchanged, average exposure decreases. Conversely, if clearance decreases, average exposure increases.

12 · Worked example

12. Worked Example: Accumulation With Repeated IV Bolus Dosing

Consider a hypothetical drug administered as a 500 mg IV bolus every 8 hours. Suppose:

  • Volume of distribution: \(V=25\) L
  • Clearance: \(CL=5\) L/h
  • Dosing interval: \(\tau=8\) h

Step 1: Calculate the elimination rate constant

\[ k=\frac{CL}{V} = \frac{5}{25} = 0.20\text{ h}^{-1} \]

Step 2: Calculate the half-life

\[ t_{1/2} = \frac{0.693}{0.20} \approx3.47\text{ h} \]

Step 3: Determine the fraction remaining after 8 hours

\[ e^{-k\tau} = e^{-0.20(8)} = e^{-1.6} \approx0.202 \]

Thus, approximately 20.2% of the concentration contribution from a dose remains after one 8-hour dosing interval.

Step 4: Calculate the accumulation ratio

\[ R_{\text{acc}} = \frac{1}{1-e^{-k\tau}} = \frac{1}{1-0.202} \approx1.253 \]

The steady-state peak is therefore approximately 1.253 times the corresponding single-dose peak.

Step 5: Calculate the single-dose peak

\[ C_0 = \frac{D}{V} = \frac{500}{25} = 20\text{ mg/L} \]

Step 6: Calculate the steady-state peak

\[ C_{\max,ss} = 20(1.253) \approx25.1\text{ mg/L} \]

Step 7: Calculate the steady-state trough

\[ C_{\min,ss} = 25.1(0.202) \approx5.07\text{ mg/L} \]

Step 8: Calculate the average steady-state concentration

\[ C_{\text{avg},ss} = \frac{D}{CL\tau} = \frac{500}{5(8)} = 12.5\text{ mg/L} \]
Result: under this simple linear one-compartment model, repeated 500 mg IV boluses every 8 hours produce a steady-state peak of approximately 25.1 mg/L, a trough of approximately 5.07 mg/L, and an average concentration of 12.5 mg/L.
13 · Oral repeated dosing

13. Multiple Oral Doses

The same accumulation principles apply to repeated oral dosing, but the concentration-time profile is affected by absorption as well as elimination.

For a one-compartment model with first-order absorption and elimination, a single oral dose can be described by:

\[ C(t) = \frac{FDk_a}{V(k_a-k)} \left(e^{-kt}-e^{-k_at}\right). \]

With repeated doses, each dose contributes another absorption-and-elimination profile. Under linear conditions, these profiles can again be summed using superposition.

Consequently, repeated oral dosing can produce accumulation even though the concentration does not jump instantaneously at the moment of dosing.

Important: for oral dosing, peak timing depends on both absorption and elimination. Therefore, the relationship between dosing interval and half-life is central to accumulation, but absorption rate also influences the shape and timing of the concentration peaks.
14 · Fluctuation

14. Accumulation Is Not the Same as Fluctuation

Two concepts are often confused:

  • Accumulation describes how much more drug is present or how much greater exposure is after repeated dosing compared with a single dose.
  • Fluctuation describes how much concentration changes within a dosing interval.

A regimen can have substantial accumulation but relatively modest peak-to-trough fluctuation, depending on the dosing interval and drug half-life.

Conversely, a short half-life combined with a relatively long dosing interval can produce substantial within-interval fluctuation even when accumulation is limited.

ConceptMain determinantTypical question
AccumulationFraction remaining at the next doseHow much does repeated dosing increase concentrations relative to a single dose?
FluctuationDose interval relative to elimination/absorption time scaleHow much does concentration change between peak and trough?
Average exposureDose rate, bioavailability, and clearanceWhat is the average steady-state concentration or exposure?
15 · Half-life

15. Why Half-Life Matters So Much

The elimination half-life influences several practical features of multiple-dose PK.

  • How much drug remains before the next dose.
  • How much accumulation occurs.
  • How rapidly steady state is approached.
  • How rapidly concentrations decline after dosing stops.
  • How much peak-to-trough fluctuation occurs for a given dosing interval.

For first-order elimination:

\[ t_{1/2}=\frac{\ln(2)}{k}. \]

For a one-compartment model:

\[ t_{1/2} = \frac{0.693V}{CL}. \]

Because half-life depends on both \(V\) and \(CL\), changes in either distribution or clearance can change the time course of accumulation and washout.

16 · After dosing stops

16. What Happens When Repeated Dosing Stops?

Once dosing stops, no new drug enters the system. The remaining drug is then eliminated according to the drug's disposition kinetics.

For first-order elimination, the concentration declines exponentially:

\[ C(t)=C_0e^{-kt}. \]

The same half-life concept used to describe the approach to steady state therefore describes the approximate time scale of washout.

Time after stoppingApproximate fraction remaining
1 half-life50%
2 half-lives25%
3 half-lives12.5%
4 half-lives6.25%
5 half-lives3.125%

Thus, the approximate time required to reach steady state and the approximate time required for washout are both governed by the elimination half-life in a simple first-order system.

17 · Regimen design

17. Choosing a Multiple-Dose Regimen

Multiple-dose regimen design involves balancing several objectives rather than focusing on a single concentration.

  • Average exposure: determined primarily by the dosing rate, bioavailability, and clearance.
  • Peak concentration: influenced by dose size, distribution, absorption, and dosing interval.
  • Trough concentration: influenced by elimination and the time between doses.
  • Accumulation: influenced strongly by the relationship between dosing interval and half-life.
  • Time to steady state: governed primarily by the elimination half-life under linear PK.

This means that a regimen can be modified in several ways. The dose can be changed, the dosing interval can be changed, or both can be changed. The resulting effects on average concentration and peak-to-trough fluctuation need to be considered separately.

Practical principle: multiple-dose PK is fundamentally a problem of balancing dose, interval, clearance, distribution, absorption, accumulation, and concentration fluctuation.
18 · When linear PK breaks down

18. What If Pharmacokinetics Are Nonlinear?

The equations in this tutorial rely heavily on linear PK assumptions. In nonlinear pharmacokinetics, the relationship between dose and concentration may change with dose or concentration.

Examples include:

  • Saturable metabolism.
  • Saturable transport.
  • Capacity-limited absorption.
  • Concentration-dependent protein binding.
  • Other processes in which clearance or bioavailability changes with concentration or dose.

In these settings, simply multiplying a single-dose profile by an accumulation factor may not accurately describe repeated dosing.

Modeling principle: before applying a standard accumulation equation, confirm that the assumptions of linear, time-invariant PK are reasonable for the drug and dose range being studied.
19 · Practical workflow

19. A Practical Multiple-Dose PK Workflow

  1. Define the regimen. Identify dose, route, and dosing interval.
  2. Identify the relevant PK model. Determine whether a one-compartment, multi-compartment, absorption, or other model is appropriate.
  3. Estimate elimination parameters. For simple first-order models, determine \(CL\), \(V\), \(k\), and \(t_{1/2}\).
  4. Compare the dosing interval with the half-life. This provides an immediate sense of the potential for accumulation.
  5. Calculate accumulation. Under appropriate linear assumptions, use the accumulation ratio.
  6. Calculate steady-state peak and trough. These help characterize within-interval fluctuation.
  7. Calculate average exposure. Relate the dosing rate to clearance.
  8. Consider time to steady state. Use the half-life to determine how quickly the regimen approaches its steady-state pattern.
  9. Check assumptions. Confirm that linear PK and the selected structural model are reasonable.
  10. Interpret clinically. Consider whether peak, trough, average exposure, and fluctuation are appropriate for the therapeutic objective.

20. Key Takeaways

  • Multiple-dose pharmacokinetics describes drug concentration behavior during repeated administration.
  • Under linear PK, repeated-dose concentrations can be understood using the principle of superposition.
  • Accumulation occurs because drug from previous doses remains when subsequent doses are administered.
  • Steady state means that the concentration-time pattern repeats from one dosing interval to the next; it does not necessarily mean that concentration is constant.
  • The accumulation ratio for first-order elimination is \(1/(1-e^{-k\tau})\).
  • Shorter dosing intervals relative to the elimination half-life generally produce greater accumulation.
  • Peak and trough concentrations describe within-interval fluctuation, whereas average steady-state concentration describes average exposure.
  • For linear PK, average steady-state concentration is determined by dosing rate, bioavailability, and clearance.
  • Approximately 4–5 half-lives are generally required to approach steady state in a simple first-order system.
  • A loading dose can be used to reach a target concentration more rapidly, while maintenance dosing replaces drug eliminated over time.
  • Repeated oral dosing involves both absorption and elimination, so peak timing depends on more than elimination alone.
  • The standard accumulation equations depend on linear, time-invariant PK assumptions and may not apply to nonlinear pharmacokinetics.
Next step

Where to Go Next

A natural progression is to study steady-state pharmacokinetics in greater detail, followed by loading and maintenance dose calculations, IV infusions, oral multiple-dose equations, accumulation with first-order absorption, and the relationship between dosing interval and peak-to-trough fluctuation.

These concepts provide the foundation for understanding therapeutic drug monitoring, dose individualization, repeated-dose PK modeling, and more advanced population PK and PK/PD analyses.

← Back to Pharmacokinetics Tutorials